Core Insights - The article promotes a workshop focused on medical device innovation and technology transfer, organized by Shanghai Jiao Tong University School of Medicine and its affiliated institutions [2][3] - The workshop aims to bridge the gap between medical needs and engineering solutions, fostering collaboration among doctors, engineers, and investors [3][4] Course Highlights - Participants will gain access to a high-end network of professionals, including doctors, researchers, industry experts, and investors, enhancing career development opportunities [3] - The workshop will cover the Biodesign innovation methodology, emphasizing the transformation of clinical needs into innovative solutions [4][10] - The program includes practical training on the complete path from concept to market for medical devices, addressing common challenges in medical innovation [4][6] Target Audience - The workshop is designed for various professionals, including doctors from different specialties, engineering personnel from research institutions, manufacturers, distributors, and entrepreneurs interested in medical device innovation [6][10] Training Structure - The training spans one and a half days, featuring intensive sessions on medical technology innovation, intellectual property management, and collaborative problem-solving [5][11] - Participants will engage in group discussions, case studies, and presentations to refine their innovative solutions and receive feedback from experts [11][12] Expert Faculty - The workshop will be led by top-tier faculty from Shanghai Jiao Tong University, including experts in biomedical engineering, medical AI, and technology commercialization [13][14][15] - The faculty has extensive experience in both academia and industry, providing valuable insights into the medical device landscape and investment opportunities [14][15][16] Registration Information - The workshop is scheduled for October 11-12, 2025, at Shanghai Jiao Tong University, with a fee of 2,800 yuan per participant [6][20] - Participants will receive a certificate of completion and continuing medical education credits upon successful completion of the workshop [20]

在北京成功举办首届论坛之后， 第二届医疗器械研发创新论坛 将于 2025年国际医疗器械设计与制造技术展览会（Medtec China2025） 期间在 上海世博 展览馆 举行。 本届论坛由思宇MedTech与Informa Markets旗下Medtec China团队联合策划，邀请企业创始人、研发负责人、科技成果转化专家等，共同 探讨产品创新的路径与落地机制。 会 议议程 （ 报 名 方 法 附 文 末 ） 日期：2025年9月25日星期四全天 上午： 09 :30-09:35 开幕 致辞 09:35-09:55 《研究型医院医工融合创新与转化工作探索》 雷娟 四川西部医药技术转移中心 理事长/主任 中国医学装备协会医疗器械创新与应用分会 副会长 09:55-10:15 《介入新技术以及相关专利》 曹刚毅 环心医疗 CEO 10:15-10:35 《打造多层次医疗科技集群：巴塞尔药谷的成功实践》 10:35-10:55 《 外科手术超声能量器械现状与创新思考 》 冯耿超 深圳市世格赛思医疗科技有限公司 创始人/CEO 10:55-11:15 《血管损伤修复与再生材料》 王恺 南开大学生命科学学院 研究员 1 ...

上海活动报名： 2025医疗器械研发创新论坛 近日，慢性疼痛创新器械提供商—— 北京新云医疗科技有限公司 （以下简称"新云医疗"）宣布完成B+轮融资。本轮融资由 道彤投资 领投， 泰州天使基金 、 乾 丰投资 等跟投，资金将主要用于核心产品的临床试验、注册申报和国际化布局。 面对中国超过3亿慢性疼痛患者、渗透率低于1%的神经调控治疗现状，以及神经病理性疼痛药物疗效不足50%的临床困境，新云医疗希望通过AI闭环脊髓电刺激 系统与微创介入产品构建新的疼痛管理路径，并打破外资在核心技术领域的长期垄断。 # 慢性疼 痛：一 个被低估的刚需 市场 慢性疼痛已被WHO列为独立的慢性疾病，全球范围内有超过20%成年人正受其困扰。在中国，疼痛相关的住院患者数量持续上升，2023年已达2615万人次，仅疼 痛科就录得35%以上的同比增长。中国疼痛患者群体总数超过3亿，且呈现显著年轻化趋势，20–40岁群体的占比已超过30%。 作为一种"看不见、摸不着"的疾病，慢性疼痛在很长时间内缺乏有效关注，其治疗长期依赖药物，但神经病理性疼痛、慢性腰背痛等类型常对药物响应不佳，有 效率不足50%。部分患者被迫选择大手术，但高风险、高成本、恢 ...

Core Viewpoint - Siemens Healthineers is in preliminary talks with top private equity firms, including Blackstone, CVC Capital, and KKR, regarding a potential sale of its diagnostics business, with an estimated valuation exceeding €6 billion (approximately ¥50 billion) [2][4][17] Group 1: Transaction Background - Siemens Healthineers is focusing on business optimization and strategic realignment, as evidenced by the sale of 2% of its shares for €1.45 billion in Q3 2025 [4] - The diagnostics segment, traditionally viewed as a "cash cow," is underperforming compared to imaging diagnostics and advanced therapies, prompting the potential sale to concentrate on higher growth and profitability areas [4] Group 2: Financial Performance - In Q3, the diagnostics business reported revenue of €1.059 billion, a 4% year-over-year decline, primarily due to price compression from China's procurement policies [8] - Despite revenue pressure, the adjusted profit margin improved to 9.2%, an increase of 180 basis points, driven by one-time projects and operational improvements [8] Group 3: Potential Buyers - Blackstone has been increasing investments in life sciences, focusing on leveraging acquisitions to enhance enterprise value [10] - CVC Capital has a broad healthcare asset portfolio in Europe and Asia, with a keen interest in the extensive market network of Siemens Healthineers' diagnostics business [11] - KKR is active in healthcare acquisitions, known for leveraging buyouts and restructuring distressed assets, with a focus on releasing business potential [12] Group 4: Industry Impact - The potential divestiture of the diagnostics business could reshape the global in vitro diagnostics (IVD) market, allowing Siemens to strengthen its focus on imaging and advanced therapies [14] - Buyers would gain immediate access to a leading laboratory diagnostics market, competing directly with giants like Roche and Abbott [14] - The impact of China's procurement policies on foreign IVD manufacturers necessitates strategic adjustments in localization, cost control, and pricing for potential buyers [14] Group 5: Uncertainty - The negotiations are still in early stages, and there is significant uncertainty regarding the completion of the transaction [16] Group 6: Conclusion - Regardless of the transaction's outcome, the news of the potential sale has opened new avenues for market speculation and could represent a significant capital event in the global IVD industry in 2025 [17]

上海活动报名： 2025医疗器械研发创新论坛 近日， 强生 （Johnson & Johnson，NYSE: JNJ）宣布，前 Sherwin-Williams（宣伟）董事长、总裁兼首 席执行官 John Morikis 正式当选为公司董事会成员 。 # 职业履历：从培训生到全球涂料巨头掌舵人 John Morikis 的职业生涯始于 1984 年，作为管理培训生加入 Sherwin-Williams 的 Paint Stores Group。 此后近 40 年，他在公司内部担任过多个要职： 他于 2023 年正式退休，但在涂料与化工领域留下了深远影响。 # 强生的考量：跨行业经验带来的补充 1990s–2000s ：逐步晋升，历任事业部总裁、集团总裁。 2006–2016 ：担任总裁兼首席运营官（COO），主导核心业务拓展。 2016–2023 ：出任董事长、总裁兼 CEO。在任 8 年间，他推动公司战略转型，将 Sherwin-Williams 的全球版图扩展至 123 个国家，并大幅优化供应链体系，同时加大对数字化和客户体验技术的投入。 强生董事长兼 CEO Joaquin Duato 表示，Morik ...

上海活动报名： 2025医疗器械研发创新论坛 2025年9月11日，深圳麦科田生物医疗技术股份有限公司（简称"麦科田"）向港交所主板递交上市申请书，联席保荐人为摩根士丹利和华泰国际。 作为一家成立于2011年的全球化医疗解决方案提供商，麦科田在过去十余年间形成了覆盖生命支持、微创介入、体外诊断三大业务板块的产品体系，业务辐射140多 个国家和地区，逐步走出一条"从制造向方案""从中国向全球"的成长路径。 此次IPO进展，亦是其获得高瓴资本、深创投等多家知名机构多年持续加持之后，迈向公开市场的关键一步。 # 三大业务协同 发力 ，形成多元 增长矩阵 自2016年起，麦科田几乎保持着"一年一轮融资"的节奏。即便在近两年全球医疗器械投融资环境趋冷的背景下，麦科田仍持续获得资本市场的信任，投资人名单中 不乏 高瓴资本、深创投 等长期关注医疗健康赛道的机构。 | | A輸融資 | B輸融資 | C輸融資 | 2020年股權轉讓 | 2021年股份認購 | 2021年股份轉讓 | 唯德康醫療股份互換 | 2023年股份認購 | 2023年股份轉讓 | 2024年股份轉讓 | | --- | --- | --- | --- ...

在北京成功举办首届论坛之后， 第二届医疗器械研发创新论坛 将于 2025年国际医疗器械设计与制造技术展览会（Medtec China2025） 期间在 上海世博 展览馆 举行。 本届论坛由思宇MedTech与Informa Markets旗下Medtec China团队联合策划，邀请企业创始人、研发负责人、科技成果转化专家等，共同 探讨产品创新的路径与落地机制。 会 议议程 （ 报 名 方 法 附 文 末 ） 日期：2025年9月25日星期四全天 上午： 09 :30-09:35 开幕 致辞 09:35-09:55 《研究型医院医工融合创新与转化工作探索》 雷娟 四川西部医药技术转移中心 理事长/主任 中国医学装备协会医疗器械创新与应用分会 副会长 09:55-10:15 《介入新技术以及相关专利》 曹刚毅 环心医疗 CEO 10:15-10:35 《打造多层次医疗科技集群：巴塞尔药谷的成功实践》 11:15-11:35 《Chro-Mg™时控降解镁合金的研发与转化》 时晨 英诺科 CEO 下午议程： 13:30-13:50 《医疗器械研发全流程及海外案例》 赵清 思宇MedTech 创始人 13:50-14 ...

文章来源： 导向医疗AccuTarget 转载要求：可以直接转载，请在文首注明来源 上海活动报名： 2025医疗器械研发创新论坛 近日，国际呼吸领域权威期刊 Respiration 发表了全球首篇 关于 机器人支气管镜（RAB）联合锥形束CT （CBCT）引导下的经支气管冷冻消融治疗肺部恶性肿瘤 的临床案例报道。该研究由上海市胸科医院孙加源 教授团队完成，采用了导向 ® 医疗的1.9mm经支气管冷冻消融针——红袖刀 ® ，成功为6例肺部恶性肿瘤患者 实施精准冷冻消融治疗，所有手术均顺利完成，无一例出现并发症。 研究背景：微创治疗的新选择 手术切除是早期非小细胞肺癌（NSCLC）和部分肺转移瘤的标准治疗方式，但对于无法耐受或拒绝手术的患 者，局部消融治疗成为重要替代方案。与传统经皮消融相比， 经支气管路径的冷冻消融 具有更低的穿刺相关 并发症（气胸、出血等）和极端位置更优越的到达能力，尤其适用于无法经皮穿刺到达或穿刺风险高的病灶。 传统的经支气管消融通常采用导航+普通支气管镜+影像设备的组合，其到达能力和精准度均有限，且局限于 有支气管通向的病灶，适用人群有限。 技术突破：机器人+CBCT+红袖刀 ® 本研究首 ...

Core Viewpoint - GE HealthCare announced its intention to acquire Icometrix, an AI brain imaging analysis company, to enhance its precision medicine strategy in the neurological field [2][13]. Company Background and Product Overview - Icometrix, founded around 2011 and headquartered in Leuven, Belgium, specializes in AI quantitative analysis of brain MRI and has become an international standard for imaging quantification of various neurological diseases [3]. - The icobrain product line has received FDA and CE mark certifications, known for its transparent and verifiable AI models, and has been awarded the "Transparent AI badge" by the American College of Radiology (ACR) [3]. Core Products and Clinical Applications - icobrain ms focuses on monitoring multiple sclerosis (MS) by automatically quantifying MRI lesions and brain volume changes, showing a 150% increase in active lesion detection rates and a 68% improvement in treatment efficacy compared to medication alone [8]. - icobrain aria, approved by the FDA in November 2024, is the first AI software for detecting, quantifying, and grading amyloid-related imaging abnormalities (ARIA) associated with Alzheimer's treatment [9]. - The icobrain system also supports a wide range of conditions, including traumatic brain injury (TBI), dementia, epilepsy, Parkinson's disease, brain tumors, and stroke, providing quantitative support for differential diagnosis and long-term follow-up [11]. Strategic Layout of GE HealthCare - GE HealthCare aims to transition from being an imaging equipment supplier to a provider of precision medical solutions, with the acquisition of Icometrix marking a significant step in its neurological strategy [13]. - The integration of Icometrix's icobrain platform with GE's MRI systems is expected to enhance the workflow for radiologists and neurologists, creating a more robust offering compared to competitors [15]. Market and Ecological Significance - The demand for imaging follow-up in neurological diseases is strong, and AI quantitative analysis can improve diagnostic quality while creating a subscription-based revenue model [19]. - By integrating Icometrix, GE not only enhances its product line but also strengthens its position in the global market by completing the "device-AI-solution" chain [19]. Challenges and Considerations - While the acquisition strengthens GE's presence in the neurological imaging field, the real challenge lies in effectively embedding Icometrix's technology into daily medical workflows and finding suitable commercial and clinical applications across different markets [20]. - The stability of AI tools in multi-center and heterogeneous data environments requires time for validation, and the impact of data differences from various MRI brands on icobrain's effectiveness remains to be observed [20]. - The commercial model for AI software is still undefined, raising questions about how hospitals and insurance systems will accept subscription-based pricing without undermining equipment profits [20].

上海活动报名： 2025医疗器械研发创新论坛 2025年9月9日， 美国 Nuwellis 公司宣布，美国国立卫生研究院（NIH）向其合作伙伴 Koronis Biomedical Technologies 授予一项约 300 万美元 （约合人民币2100万） 的多年期科研资助，用于开发 一款面向 低体重儿童的连续性肾脏替代治疗（CRRT）设备 Vivian 系统 。 这笔资金将支持 Vivian 的软件与固件开发，并资助在美国开展约 15 名患者入组的 首个 FDA 临床研究 。 该计划由 Koronis Biomedical 负责执行，Nuwellis 保留相关技术和知识产权。 # Vivian：为体重不足 20 公斤儿童设计的专用系统 儿科肾脏替代的临床痛点 目前针对 20 公斤以下患儿的人工肾支持选择极为有限。临床医生通常只能改造成人用设备以勉强应用在小 体重患者身上，但这在血容量控制、操作安全性、监测精度等方面均存在不足。 技术参数与功能设计 Vivian 面向 2.5–20 公斤 的儿童患者，目标体外循环血容量仅 29–67 mL ，更贴合低体重人群的血流耐 受。系统关键特点包括： 多模式融合 ： ...